U.S. markets open in 3 hours 56 minutes
  • S&P Futures

    3,882.50
    -16.25 (-0.42%)
     
  • Dow Futures

    31,424.00
    -85.00 (-0.27%)
     
  • Nasdaq Futures

    13,220.00
    -59.75 (-0.45%)
     
  • Russell 2000 Futures

    2,255.90
    -18.90 (-0.83%)
     
  • Crude Oil

    60.71
    +0.07 (+0.12%)
     
  • Gold

    1,725.80
    +2.80 (+0.16%)
     
  • Silver

    26.30
    -0.38 (-1.42%)
     
  • EUR/USD

    1.2024
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.62
    -4.33 (-15.49%)
     
  • GBP/USD

    1.3880
    -0.0041 (-0.29%)
     
  • USD/JPY

    106.8630
    +0.1330 (+0.12%)
     
  • BTC-USD

    49,061.93
    +1,844.64 (+3.91%)
     
  • CMC Crypto 200

    987.03
    +0.38 (+0.04%)
     
  • FTSE 100

    6,616.31
    +27.78 (+0.42%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT.

A webcast of the presentation will be available in the investors section of the Company’s website www.catabasis.com, and will be archived for 30 days following the presentation.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005033/en/

Contacts

Investor and Media Contact
Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com